Cargando…

Targeted Therapies for Melanoma

The incidence of cutaneous malignant melanoma is increasing worldwide. Despite available modern therapeutical options, long-term survival of patients in advanced stages of the disease remains rather limited until now. Detailed insights into etiopathogenesis and mechanisms of tumour progression enabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Smetana, Karel, Lacina, Lukáš, Kodet, Ondřej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565572/
https://www.ncbi.nlm.nih.gov/pubmed/32899184
http://dx.doi.org/10.3390/cancers12092494
_version_ 1783595963599814656
author Smetana, Karel
Lacina, Lukáš
Kodet, Ondřej
author_facet Smetana, Karel
Lacina, Lukáš
Kodet, Ondřej
author_sort Smetana, Karel
collection PubMed
description The incidence of cutaneous malignant melanoma is increasing worldwide. Despite available modern therapeutical options, long-term survival of patients in advanced stages of the disease remains rather limited until now. Detailed insights into etiopathogenesis and mechanisms of tumour progression enable physicians to manipulate distinct molecular structures and pathways therapeutically and so treat the tumour. Unfortunately, the acquisition of therapeutic resistance frequently terminates these therapeutical interventions. The presented special issue is focusing on the research and therapeutic experience of leading scientists, and it summarises the state of the art of targeted therapy of melanoma and suggests the new perspectives of the treatment of disease.
format Online
Article
Text
id pubmed-7565572
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75655722020-10-26 Targeted Therapies for Melanoma Smetana, Karel Lacina, Lukáš Kodet, Ondřej Cancers (Basel) Editorial The incidence of cutaneous malignant melanoma is increasing worldwide. Despite available modern therapeutical options, long-term survival of patients in advanced stages of the disease remains rather limited until now. Detailed insights into etiopathogenesis and mechanisms of tumour progression enable physicians to manipulate distinct molecular structures and pathways therapeutically and so treat the tumour. Unfortunately, the acquisition of therapeutic resistance frequently terminates these therapeutical interventions. The presented special issue is focusing on the research and therapeutic experience of leading scientists, and it summarises the state of the art of targeted therapy of melanoma and suggests the new perspectives of the treatment of disease. MDPI 2020-09-03 /pmc/articles/PMC7565572/ /pubmed/32899184 http://dx.doi.org/10.3390/cancers12092494 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Smetana, Karel
Lacina, Lukáš
Kodet, Ondřej
Targeted Therapies for Melanoma
title Targeted Therapies for Melanoma
title_full Targeted Therapies for Melanoma
title_fullStr Targeted Therapies for Melanoma
title_full_unstemmed Targeted Therapies for Melanoma
title_short Targeted Therapies for Melanoma
title_sort targeted therapies for melanoma
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565572/
https://www.ncbi.nlm.nih.gov/pubmed/32899184
http://dx.doi.org/10.3390/cancers12092494
work_keys_str_mv AT smetanakarel targetedtherapiesformelanoma
AT lacinalukas targetedtherapiesformelanoma
AT kodetondrej targetedtherapiesformelanoma